Amphastar Pharma slips on deal to buy Eli Lilly's low blood sugar drug
** Amphastar Pharmaceuticals Inc AMPH.O shares down 5.5% at
$41.4
** Eli Lilly and Co LLY.N will sell its low blood sugar
drug Baqsimi to Amphastar in a deal worth up to $1.08 billion
urn:newsml:reuters.com:*:nL4N36R27L
** Amphastar will pay $500 million at closing and another
$125 million in cash after one year under the deal
** Up to last close, AMPH rose 56.5%
(Reporting by Nandhini Srinivasan in Bengaluru)
((nandhini.srinivasan@thomsonreuters.com))
Recent news on Amphastar Pharmaceuticals
See all newsAmphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Amphastar Pharmaceuticals Q2 EPS USD 0.67
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Amphastar rises after FDA approves new over-the-counter overdose spray